Nektar's breast cancer drug fails Phase III trial
This article was originally published in Scrip
Executive Summary
Nektar Therapeutics says topline results from its Phase III BEACON study evaluating single-agent NKTR-102 in patients with advanced breast cancer show that it failed to meet its primary endpoint. However, the company still sees a future for the drug in certain subsets of patients.